AstraZeneca
Health / Medicine Related News
The US rejection of the Anglo-Swedish drugmaker's blood clot-reducing drug Bilinta is a blow for the industry
Source: FT.com - Pharmaceuticals
Drug failure leaves AstraZeneca depressed
Pharmaceutical group misses out on FTSE rebound after tests showed promising new treatment had no clear benefit over a placebo
Source: FT.com - Pharmaceuticals
AstraZeneca chiefs total pay surges
Bonuses and shares push David Brennans package to more than £9m, despite concerns over the future of the Anglo-Swedish pharmaceutical group
Source: Pharmaceuticals companies news from the Financial Times
AstraZeneca to pay $1.3bn for Ardea
The agreement to purchase the US biotechnology company seeks to secure future sales before patents for key medicines expire
Source: Pharmaceuticals companies news from the Financial Times
AstraZenecas new chief suspends buybacks
Pascal Soriots action will retain the unspent $2.2bn from the companys $4.2bn buyback programme and help fund potential acquisitions
Source: Pharmaceuticals companies news from the Financial Times
AstraZeneca cuts 1600 jobs in UK and US
Pharma group to take $1.4bn charge as restructuring will see shift from Alderley Park to new research hub and global HQ in Cambridge
Source: Pharmaceuticals companies news from the Financial Times
AstraZeneca wins US drug patent case
Judgment defers cut-price competition on cholesterol drug Crestor with generic companies Actavis and Egis ordered to pay royalties until May 2016
Source: Pharmaceuticals companies news from the Financial Times